KR20170018225A - Pharmaceutical composotion for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein - Google Patents
Pharmaceutical composotion for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein Download PDFInfo
- Publication number
- KR20170018225A KR20170018225A KR1020150111561A KR20150111561A KR20170018225A KR 20170018225 A KR20170018225 A KR 20170018225A KR 1020150111561 A KR1020150111561 A KR 1020150111561A KR 20150111561 A KR20150111561 A KR 20150111561A KR 20170018225 A KR20170018225 A KR 20170018225A
- Authority
- KR
- South Korea
- Prior art keywords
- fusion protein
- protein
- hsp22
- tat
- cell
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 104
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 104
- 101710113889 Heat shock protein 22 Proteins 0.000 title claims abstract description 57
- 208000028867 ischemia Diseases 0.000 title abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 201000006474 Brain Ischemia Diseases 0.000 claims description 24
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 23
- 206010008118 cerebral infarction Diseases 0.000 claims description 23
- 101710149951 Protein Tat Proteins 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 63
- 230000001681 protective effect Effects 0.000 abstract description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 10
- 238000013467 fragmentation Methods 0.000 abstract description 8
- 238000006062 fragmentation reaction Methods 0.000 abstract description 8
- 210000002569 neuron Anatomy 0.000 abstract description 8
- 238000010171 animal model Methods 0.000 abstract description 7
- 230000003833 cell viability Effects 0.000 abstract description 7
- 230000006907 apoptotic process Effects 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 6
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 230000030833 cell death Effects 0.000 abstract description 3
- 210000001320 hippocampus Anatomy 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000001052 transient effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 210000003061 neural cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 31
- 230000032258 transport Effects 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 21
- 230000036542 oxidative stress Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 4
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 4
- 108010088535 Pep-1 peptide Proteins 0.000 description 4
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002025 microglial effect Effects 0.000 description 3
- 230000009223 neuronal apoptosis Effects 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 241001282736 Oriens Species 0.000 description 2
- IWNOFCGBMSFTBC-CIUDSAMLSA-N Pro-Ala-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IWNOFCGBMSFTBC-CIUDSAMLSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- SKPQXOSVPKPXML-ULQDDVLXSA-N 2-[[(2s)-1-[(2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NCCC1)CC1=CC=CC=C1 SKPQXOSVPKPXML-ULQDDVLXSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- XUVTWGPERWIERB-IHRRRGAJSA-N Asp-Pro-Phe Chemical compound N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O XUVTWGPERWIERB-IHRRRGAJSA-N 0.000 description 1
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 1
- XOASPVGNFAMYBD-WFBYXXMGSA-N Asp-Trp-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O XOASPVGNFAMYBD-WFBYXXMGSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- UJMNFCAHLYKWOZ-DCAQKATOSA-N Glu-Lys-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UJMNFCAHLYKWOZ-DCAQKATOSA-N 0.000 description 1
- JPUNZXVHHRZMNL-XIRDDKMYSA-N Glu-Pro-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JPUNZXVHHRZMNL-XIRDDKMYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QSVCIFZPGLOZGH-WDSKDSINSA-N Gly-Glu-Ser Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QSVCIFZPGLOZGH-WDSKDSINSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- IGOYNRWLWHWAQO-JTQLQIEISA-N Gly-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-JTQLQIEISA-N 0.000 description 1
- 101150031301 HSP22 gene Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101001047341 Homo sapiens Heat shock protein beta-8 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 1
- JZBVBOKASHNXAD-NAKRPEOUSA-N Ile-Val-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N JZBVBOKASHNXAD-NAKRPEOUSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- DLFAACQHIRSQGG-CIUDSAMLSA-N Leu-Asp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DLFAACQHIRSQGG-CIUDSAMLSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- YVSHZSUKQHNDHD-KKUMJFAQSA-N Lys-Asn-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N YVSHZSUKQHNDHD-KKUMJFAQSA-N 0.000 description 1
- KKFVKBWCXXLKIK-AVGNSLFASA-N Lys-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)N KKFVKBWCXXLKIK-AVGNSLFASA-N 0.000 description 1
- QFSYGUMEANRNJE-DCAQKATOSA-N Lys-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N QFSYGUMEANRNJE-DCAQKATOSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VHGIWFGJIHTASW-FXQIFTODSA-N Met-Ala-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O VHGIWFGJIHTASW-FXQIFTODSA-N 0.000 description 1
- MQASRXPTQJJNFM-JYJNAYRXSA-N Met-Pro-Phe Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MQASRXPTQJJNFM-JYJNAYRXSA-N 0.000 description 1
- LPNWWHBFXPNHJG-AVGNSLFASA-N Met-Val-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN LPNWWHBFXPNHJG-AVGNSLFASA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- HTTYNOXBBOWZTB-SRVKXCTJSA-N Phe-Asn-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HTTYNOXBBOWZTB-SRVKXCTJSA-N 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- BNRFQGLWLQESBG-YESZJQIVSA-N Phe-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BNRFQGLWLQESBG-YESZJQIVSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 1
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 1
- AJNGQVUFQUVRQT-JYJNAYRXSA-N Pro-Pro-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 AJNGQVUFQUVRQT-JYJNAYRXSA-N 0.000 description 1
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- COLJZWUVZIXSSS-CIUDSAMLSA-N Ser-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N COLJZWUVZIXSSS-CIUDSAMLSA-N 0.000 description 1
- UAJAYRMZGNQILN-BQBZGAKWSA-N Ser-Gly-Met Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UAJAYRMZGNQILN-BQBZGAKWSA-N 0.000 description 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- YXEYTHXDRDAIOJ-CWRNSKLLSA-N Ser-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N)C(=O)O YXEYTHXDRDAIOJ-CWRNSKLLSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 1
- SPIFGZFZMVLPHN-UNQGMJICSA-N Thr-Val-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SPIFGZFZMVLPHN-UNQGMJICSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- WMIUTJPFHMMUGY-ZFWWWQNUSA-N Trp-Pro-Gly Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)NCC(=O)O WMIUTJPFHMMUGY-ZFWWWQNUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 1
- PQPWEALFTLKSEB-DZKIICNBSA-N Tyr-Val-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PQPWEALFTLKSEB-DZKIICNBSA-N 0.000 description 1
- HQYVQDRYODWONX-DCAQKATOSA-N Val-His-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N HQYVQDRYODWONX-DCAQKATOSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 102000046085 human HSPB8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 238000002712 mitochondrial membrane potential assay Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
Abstract
Description
The present invention relates to a pharmaceutical composition for treating cerebral ischemia comprising a cell permeable heat shock protein 22 fusion protein, wherein the heat shock protein 22 fusion protein permeated into the cell has an increased cell survival rate against hydrogen peroxide toxicity, Induced DNA fragmentation. In the animal model, the heat shock protein 22 fusion protein showed a protective effect against the neuronal apoptosis induced by inducing transient ischemia in the CA1 part of the whole hippocampus. These results indicate that the heat shock protein 22 fusion protein has a protective effect against apoptosis and has a therapeutic effect for protecting nerve cells from damage of cerebral ischemia.
Due to a variety of causes, the blood vessels to the brain block, blocking glucose and oxygen, which are essential for brain function. Continuous energy supply and oxygen deficiency lead to oxidative stress leading to stroke, total cerebral ischemia or severe brain damage. When ischemic reperfusion proceeds, reactive oxygen species are produced in the mitochondria of brain cells. The resulting reactive oxygen species will lead to neurodegenerative brain diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
In order to transfer a therapeutic drug or protein into a cell, a method of directly delivering the target protein through the cell membrane may be considered. However, proteins are very difficult to pass through cell membranes because of their size and various biochemical properties. In general, substances with a molecular weight of 600 Daltons or more are known to be almost impossible to pass through cell membranes.
It has been found that the Tat (Transactivator of transcription) peptide, a type of human immunodeficiency virus type-1 protein, efficiently migrates into the cytoplasm through the cell membrane. This function is due to the characteristics of the protein transduction domain, which is the middle part of the Tat peptide, and the precise mechanism is still unknown. It is also known that the PEP-1 protein transport domain also covalently binds to other proteins and smoothly transports the other proteins into the cells. Recent studies have shown that other proteins are directly transported into cells and tissues when fused with HIV-1 Tat peptide, PEP-1 peptide, oligo lysine, oligoarginine, oligo (lysine + arginine)
However, not all of the proteins can be permeated into the cell via the protein transport domain and the fusion protein. In 2001, 2004 and 2007, it was reported that the proteins bound to Tat transduction sites were introduced into cells but did not show activity (Sengoku, T. et al. Experimental Neurology 188 (2004) 161-170, Falnes PO et al. Biochemistry 2001 Apr 10; 40 (14): 4349-4358, Daniele Peroni et al., Neuroscience letters 421 (2007) 110-114, etc.). That is, when the protein transport domain is fused to a protein which is not easily introduced into cells through the above-mentioned references, it can be seen that all the fused proteins are not activated smoothly after being introduced into the cells.
It is an object of the present invention to provide a composition capable of effectively preventing and treating brain ischemic injury.
Heat Shock protein 22 (HSP22) is an antioxidant enzyme that plays an important role in various diseases. However, HSP22 has been known to play an important role in cytoprotection, neurodegeneration and apoptosis of reactive oxygen species in mitochondria in some studies, but mechanisms and functions for the prevention or treatment of cerebral ischemia are unknown. Thus, we have studied the protective effect of the Tat-HSP22 fusion protein on oxidative stress in neuronal and brain ischemia animal models by recombining HIV-Tat peptide, one of the protein transport domains, with HSP22 protein. As a result, we confirmed that Tat-HSP22 fusion protein has a protective effect against apoptosis induced by oxidative stress and explored the possibility of being useful for the treatment of oxidative stress related diseases such as brain diseases.
The present invention relates to a pharmaceutical composition for preventing or treating cerebral ischemia comprising a heat shock protein 22 fusion protein in which a Tat peptide is covalently bonded to the N-terminus of a heat shock protein 22.
In addition, the present invention relates to a pharmaceutical composition for preventing or treating cerebral ischemia comprising the heat shock protein 22 fusion protein, wherein the heat shock protein 22 fusion protein is composed of the amino acid sequence of SEQ ID NO: 2.
In one embodiment of the present invention, the present inventors first developed an HSP22 expression vector capable of overexpressing and easily purifying an HSP22 fusion protein. This expression vector contains a human HSP22 protein, a Tat protein transport domain, and a cDNA capable of expressing six histidine residues at the amino terminal end.
Using this expression vector, the HSP22 fusion protein was overexpressed in E. coli and purified using Ni-affinity chromatography. Western blotting confirmed that the HSP22 fusion protein was delivered to the cells in a time- and concentration-dependent manner in the cultured cells. The HSP22 fusion protein permeated into the cells was maintained in the cells for up to 24 hours and inhibited cell death by oxidative stress.
These results indicate that the HSP22 fusion protein is well permeated into the cell and is well expressed in the function of the HSP22 protein in the cell. Therefore, this HSP22 fusion protein provides a possibility to apply to brain diseases such as diseases associated with reactive oxygen species or protection of nerve cells from damage of cerebral ischemia.
The pharmaceutical composition containing the cell-permeable HSP22 fusion protein as an active ingredient can be formulated together with a carrier that is conventionally acceptable in the pharmaceutical field, and can be formulated by an ordinary method, such as oral or injection form. Oral compositions include, for example, tablets and gelatin capsules, which may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine, , Magnesium stearate, stearic acid and its magnesium or calcium salt and / or polyethylene glycol) and the tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone ), And may optionally contain a disintegrant (e.g., starch, agar, alginic acid or a sodium salt thereof) or a boiling mixture and / or an absorbent, a colorant, a flavoring agent and a sweetening agent. The injectable composition is preferably an isotonic aqueous solution or suspension, and the composition mentioned is sterilized and / or contains adjuvants such as preservatives, stabilizers, wetting or emulsifying solution accelerators, salts for controlling osmotic pressure and / or buffering agents. They may also contain other therapeutically valuable substances.
The pharmaceutical preparation thus prepared may be administered orally, parenterally, that is, intravenously, subcutaneously, intraperitoneally, or topically, depending on the purpose, and in the case of application to asthma, As known to those of ordinary skill in the art, it can be formulated into a formulation by inhalation or spray. The dose may be administered in a single daily dose of 0.0001 to 100 mg / kg dividedly in several doses. The dosage level for a particular patient may vary depending on the patient's body weight, age, sex, health condition, time of administration, method of administration, excretion rate, severity of disease, and the like.
Further, the present invention provides a pharmaceutical composition useful for the prevention and treatment of cerebral ischemia, which comprises the HSP22 fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
The present invention also provides a method for efficiently delivering HSP22 protein into a cell. Intracellular delivery of the HSP22 protein molecule according to the present invention is carried out by constructing a fusion protein in which the protein transport domain including the Tat peptide is covalently bonded. Examples of the transport domain of the present invention include PEP-1 peptide, Tat peptide, oligo lysine, and the like. However, the protein transport domain of the present invention is not limited to a Tat peptide, and it may be desirable to prepare a peptide having a function similar to that of a Tat peptide due to partial substitution, addition or deletion of the amino acid sequence of Tat, It is obvious to those skilled in the art that the Tat protein transport domain and the fusion protein using the peptide transport domain and the protein transduction domain that carry out the same or similar protein transport function as a partial amino acid substitution therefrom also fall within the scope of the present invention will be.
Specifically, the present invention relates to an HSP22 fusion protein, a pharmaceutical composition for treating or preventing cerebral ischemia comprising the fusion protein.
The definitions of the main terms used in the description of the present invention and the like are as follows.
"HSP22 fusion protein" means a covalent binding complex formed by genetic fusion or chemical bonding between a protein transport domain and an HSP22 protein, and a transport domain and a target protein (i.e., HSP22 protein in the present invention). In this specification, "Tat-HSP22 "," Tat-HSP22 fusion protein "
"Target protein" is a molecule which is not originally able to enter the target cell, or which is not a transport domain or a fragment thereof that can not enter the target cell at an inherently useful speed, as a molecule itself before being fused with the transport domain, Means the target protein portion. The target protein includes a polypeptide, a protein, and a peptide, and the term " HSP22 protein "
"Fusion protein" means a complex comprising a transport domain and one or more target protein fragments, formed by genetic fusion or chemical bonding of the transport domain and the target protein.
In addition, the term "genetic fusion" means a link consisting of a linear, covalent bond formed through genetic expression of a DNA sequence encoding a protein.
The term "target cell" refers to a cell to which a target protein is delivered by a transport domain, and the target cell refers to a cell in the body or in vitro. That is, the target cell is meant to include a body cell, that is, a living animal, or a cell or living organism of a human organ or tissue, or a microorganism found in a human being. In addition, the target cell means an extracellular cell, that is, a cultured animal cell, a human cell or a microorganism.
The term "protein transport domain" in the present invention refers to a protein transport domain that is covalently bonded to a polymer organic compound such as an oligonucleotide, peptide, protein, oligosaccharide or polysaccharide to introduce the organic compound into cells without requiring additional receptor, It can be said.
Also, in the present specification, the terms "transport", "penetration", "transport", "delivery", "permeation" and "passage" are used interchangeably with respect to "introducing" proteins, peptides and organic compounds into a cell.
The HSP22 fusion protein of the present invention refers to an HSP22 fusion protein in which the protein transduction domain is covalently bound to at least one terminal of HSP22 to improve cell penetration efficiency. Also, the transport domain refers to at least one of HIV Tat 49-57 residue, PEP-1 peptide, oligo lysine, oligoarginine or oligo (lysine, arginine).
In addition, the HSP22 fusion protein amino acid sequence of the present invention comprises SEQ ID NO: 4. The fusion protein of various sequences can be obtained according to the selection of the restriction site sequence in the production of the HSP22 fusion protein, and this is obvious to a person having ordinary skill in the art. It is obvious that the above amino acid sequence is only exemplary and the amino acid sequence of HSP22 fusion protein is not limited to the above sequence.
The present invention also provides a pharmaceutical composition comprising the HSP22 fusion protein as an active ingredient and a pharmaceutically acceptable carrier, for the prevention and treatment of cerebral ischemia.
The present invention also provides a health functional food composition comprising the HSP22 fusion protein as an active ingredient and having an effect of preventing and ameliorating cerebral ischemia.
The present invention relates to a cell-transducing HSP22 fusion protein in which a protein transport domain is covalently bonded to at least one end of an HSP22 protein. Also, depending on the silent change, one or more amino acids within the sequence may be replaced with other amino acid (s) of similar polarity functionally equivalent. Amino acid substitutions in the sequence may be selected from other members of the class to which the amino acid belongs.
For example, the hydrophobic amino acid class includes alanine, valine, leucine, isoleucine, phenylalanine, valine, tryptophan, proline and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. Positive basic amino acids include arginine, lysine and histidine. Acidic amino acids with negative charge include aspartic acid and glutamic acid. Also included within the scope of the invention are fragments or derivatives thereof having homologous homology, for example within the range of 85-100%, between the fusion protein of the present invention and the amino acid sequence, having the same similar biological activity.
The nucleic acid sequence and the amino acid sequence of Table 1 below illustrate one embodiment of the nucleic acid sequence encoding the Tat-HSP22 fusion protein and the amino acid sequence of the Tat-HSP22 fusion protein, respectively, but the nucleic acid sequence encoding the Tat- It will be apparent to those skilled in the art that the amino acid sequence of the HSP22 fusion protein is not limited to the sequence shown in Table 1. [
GGATCC
In the present invention, the Tat-HSP22 fusion protein permeated into cells increased the cell survival rate to hydrogen peroxide toxicity. In addition, the Tat-HSP22 fusion protein of the present invention reduced intracellular reactive oxygen species levels and hydrogen peroxide-induced DNA fragmentation. In addition, the Tat-HSP22 fusion protein of the present invention showed a protective effect against the neuronal apoptosis that occurs when transient ischemia was induced in the CA1 region of the hippocampus in the animal model. From these results, it can be seen that the cell-permeable Tat-HSP22 fusion protein of the present invention can be used as a pharmaceutical composition for preventing and treating cerebral ischemia.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph showing a construction diagram and purification of a Tat-HSP22 fusion protein. FIG. 1A is a schematic diagram of a constructed Tat-HSP22 fusion protein. The Tat-HSP22 fusion protein contains a His tag consisting of six histidine residues. The purified fusion protein was analyzed by 12% SDS-PAGE (left of FIG. 1b) and Western blot analyzed with anti-rabbit polyhistidine antibody (right of FIG. 1b).
Figure 2 shows the results of an experiment in which the Tat-HSP22 fusion protein is permeated into HT22 cells. The cells were cultured in a 60 mm culture dish and treated with Tat-HSP22 fusion protein at a concentration (0.5 to 5 μM) and added to the culture medium for 2 hours. As a control, HSP22 protein without a protein transduction domain was used (FIG. 2A). In addition, a 5 占 농도 concentration of Tat-HSP22 fusion protein was added to the culture medium for 10 to 120 minutes (Fig. 2b). This was analyzed by Western blotting. The stability of the Tat-HSP22 fusion protein permeated into the cells was evaluated by Western blotting (Fig. 2c) after treatment of the 5 占 Tat Tat-HSP22 fusion protein for 2 hours and then with different times (1-60 h). The intracellular distribution of the Tat-HSP22 fusion protein permeated into the cells was observed with a confocal microscope (Fig. 2d). Size bar = 20 mm.
FIG. 3 shows the cytotoxic effect of Tat-HSP22 fusion protein on cell viability, DCF-DA, DNA fragmentation after addition of H 2 O 2 . H 2 O 2 (1 mM 12 h) was added to HT22 cells pretreated with Tat-HSP22 (5 mM) for two hours. Cell viability was evaluated by colorimetric assay using MTT (Fig. 3A). ** P and 0.01 are values compared with cells treated with H 2 O 2 . The effect of the Tat-HSP22 fusion protein on cells that induced the production of reactive oxygen species with H 2 O 2 was tested. For two hours, cells were treated with Tat-HSP22 fusion protein and stimulated with 1 mM H 2 O 2 for 5 minutes. Intracellular reactive oxygen species levels were measured after staining with DCF-DA and fluorescence intensity was measured with an ELISA plate reader (Fig. 3B). Size bar = 25 mm. * P and 0.01 are values compared with cells treated with H 2 O 2 alone. Cells were treated with Tat-HSP22 fusion protein (5 mM) for two hours and then exposed to H 2 O 2 (1 mM) for four hours. DNA fragmentation was detected by TUNEL staining. Size bar = 50 mm.
Figure 4 shows the effect of permeable Tat-HSP22 fusion protein on H 2 O 2 -induced mitochondrial membrane potential activation. Mitochondrial membrane potential was detected using a mitochondrial membrane potential assay kit (Fig. 4C). Size bar = 50 mm. Cells were treated with Tat-HSP22 fusion protein (5-0.3 mM) for two hours and then exposed to H 2 O 2 (1 mM). Bax and Bcl-2 were detected by Western blotting and the band intensity was measured by density meter (FIG. 4b). * P and 0.01 are values compared with cells treated with H 2 O 2 alone.
Figure 5 shows the results of NeuN immunohistochemistry analysis of neuronal cell viability. Immunohistochemistry using histidine antibody showed that the Tat-HSP22 fusion protein permeated across the blood-brain barrier. Sham group, carrier group, Tat peptide treated group, HSP22 protein treated group and Tat-HSP22 fusion protein treated group were analyzed by immunohistochemistry after 7 days of cerebral ischemia / reperfusion. SP: stratum pyramidale, SO: stratum oriens, SR: stratum radiatum. Relative analysis of the number of immunoreactive neurons is a significant difference from the carrier group. * P <0.01 compared with the carrier group. Size bar = 50 μm.
FIG. 6 is a result of immunohistochemical analysis of the neuroprotective effect of Tat-HSP22 fusion protein permeated into cells. Immunohistochemistry for CV, GFAP, Iba-1 and FJB in the CA1 region of the Tat-HSP22 fusion protein-treated group was performed 7 days after cerebral ischemia / reperfusion Respectively. SP: stratum pyramidale, SO: stratum oriens, SR: stratum radiatum. Relative analysis of the number of immunoreactive neurons is a significant difference from the carrier group. * P <0.01 compared with the carrier group. Size bar = 50 μm.
Hereinafter, the configuration of the present invention will be described in more detail with reference to specific embodiments. However, it is apparent to those skilled in the art that the scope of the present invention is not limited to the scope of the embodiments.
1) Purification of Tat-HSP22 fusion protein and cell permeation
In order to prepare the permeable Tat-HSP22 fusion protein, Tat vector containing Tat, which is a kind of protein transduction domain (PTD), and HSP22 gene were recombined (Fig. 1A) and overexpressed in E. coli to produce Ni 2 + Purification was carried out using a leuracetate sepharose affinity chromatography column and PD-10 column chromatography, and confirmed by SDS-PAGE and Western blotting (Fig. 1B).
To determine whether the Tat-HSP22 fusion protein infiltrated into cells, HT-22 cells were treated with hippocampal neuronal cells at different times and concentrations. As a result, intracellular permeation was effectively effected in a time- and concentration-dependent manner, and HSP22 protein not bound with negative control (Control) and protein transduction domain Tat did not permeate (Figs. 2a and 2b). The nucleus was stained with DAPI using a confocal microscope, and the Tat-HSP22 fusion protein was stained with green fluorescence to be effectively penetrated into the cells (FIG. 2d). The permeabilized fusion protein was stably maintained in the cells for 24 hours (Fig. 2C).
2) Protection effect of Tat-HSP22 fusion protein on cell viability, reactive oxygen species level and DNA fragmentation due to oxidative stress
The cells were pretreated with Tat-HSP22 fusion protein at different concentrations and then subjected to oxidative stress with H 2 O 2 . MTT {3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide} analysis was performed to confirm cell viability. Single-treatment of hippocampal neuron HT-22 cells with 1 mM H 2 O 2 reduced the number of viable cells to 56%, but when the Tat-HSP22 fusion protein was treated, the cell viability was increased in a concentration-dependent manner ).
In addition, in order to confirm that Tat-HSP22 fusion protein effectively suppresses the increase of reactive oxygen species due to H 2 O 2 , active oxygen species generated in the cell and H 2 DCFDA (2 ', 7'-dichlorofluorescin diacetate) (2 ', 7'-dichloro-fluorescein) by hydrolysis and hydrolysis of impermeable H 2 DCF (2', 7'-dichlorofluorescin) by reaction with DCF-DA staining method . In the H 2 O 2 -treated cells, the green fluorescence was strongly colored by lipopolysaccharide (LPS) compared to the control HSP22 protein, whereas the permeable Tat-HSP22 fusion protein reduced the fluorescence signal (FIG.
The protection effect against DNA fragmentation caused by oxidative stress was examined by TUNEL staining method using fluorescent pigment which specifically attaches to the fragmented part of DNA. The experiment was carried out in the same condition as the previous experiment, and it was confirmed that the Tat-HSP22 fusion protein had a protective effect against DNA fragmentation (FIG. 3C).
3) Protective effect of Tat-HSP22 fusion protein on mitochondrial damage
The activity of mitochondria was confirmed by JC-1 staining. JC-1 staining is a technique to measure mitochondrial membrane permeabilization (MMP) of mitochondria damaged by oxidative stress. When mitochondrial membrane permeation is damaged, JC-1 can not penetrate and is present as a monomer. , Whereas when the membrane permeation proceeds normally, the JC-1 staining material aggregates to form a j-aggregate, resulting in red fluorescence. H 2 O 2 treated with the Tat-HSP22 fusion protein protected the damage to the oxidative stress, whereas the membrane permeation damage was reduced, resulting in red fluorescence (Fig. 4A).
The expression level of Bcl-2 and Bax during cell death in mitochondria was examined. Treatment of H 2 O 2 resulted in a decrease in Bcl-2 expression and a marked increase in Bax expression. In the case of treatment with Tat-HSP22 fusion protein, the expression of Bcl-2 was increased in a concentration-dependent manner similar to the negative control without any treatment , And the expression of Bax was markedly decreased (Fig. 4B).
4) Confirmation of penetration of Tat-HSP22 fusion protein in an animal model inducing cerebral ischemia
In order to confirm the protective effect of Tat-HSP22 fusion protein on neurons, immunohistochemical staining was performed. In the experimental group without the Tat-HSP22 fusion protein, the number of cells stained with NeuN (neuronal nuclei) antibody decreased significantly in the CA1 region of Zeville while the number of cells stained with Tat-HSP22 fusion protein was decreased The inhibition of CA1 local neuronal apoptosis was confirmed by NeuN antibody staining. In addition, the penetration of Tat-HSP22 fusion protein into the tissue was confirmed by anti-histidine antibody, and nuclear staining was confirmed by DAPI (FIG. 5).
5) Cytoprotective effect of Tat-HSP22 fusion protein on ischemic brain injury
In order to examine the protective effect of Tat-HSP22 fusion protein against ischemic brain injury, Hybil rats were used to reduce cerebral blood flow continuously to induce brain hypoxia and cerebral ischemia, Animal models were constructed using surgical procedures to induce neuronal death through acute ischemic injury. Tissue fluorescence using F-JB (Fluoro-Jade B) staining of damaged brain cells with CV (Cresyl Violet) staining, which stains live cells only to see if the infiltrated Tat-HSP22 fusion protein protects against cerebral ischemia (histofluorescent) staining. Among animal models inducing cerebral ischemia, Tat-HSP22 fusion protein-treated animals showed protection against apoptosis, whereas animals treated with the control HSP22 protein showed no protective effect against apoptosis. In addition, Iba-1 (ionized calcium-binding adapter molecule 1) is a new Ca ++ -binding protein, specifically expressed in brain activated microglia. Thus, Iba-1 is used as a marker for micrographs in these studies, confirming activation of microglial cells by neuronal death. Also, GFAP (Glial fibrillary acidic protein), which is a component of intermediate fibers (intermediate filament) and a marker of astrocytes, was also used. GFAP is a protein that is expressed when activated to compensate for damage to astrocyte cells, especially when damaged, and it can be observed that astrocytes are activated and aggregated when brain damage occurs. The effect of Tat-HSP22 fusion protein on microglial and astrocytic activity and aggregation in the cerebral ischemia model was confirmed. As a result, it was confirmed that when the ischemia induced, the activity of the stained microglial cells and astrocytes increased and coagulated with each other, whereas when the Tat-HSP22 fusion protein was treated, the activation and aggregation phenomena decreased 6).
Therefore, the present invention suggests that Tat-HSP22 fusion protein can be effectively applied as a therapeutic agent for neurodegenerative diseases such as cerebral ischemia due to oxidative stress and various diseases.
<110> Industry Academic Cooperation Foundation, Hallym University <120> Pharmaceutical composition for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein <130> HallymU-SYCHOI-HSP22-ischemia <160> 2 <170> Kopatentin 2.0 <210> 1 <211> 678 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide coding Tat-HSP22 fusion protein <400> 1 catcatcatc atcatcacag cagcggcctg gtgccgcgcg gcagccatag gaagaagcgg 60 agacagcgac gaagactcga gatggctgac ggtcagatgc ccttctcctg ccactaccca 120 agccgcctgc gccgagaccc cttccgggac tctcccctct cctctcgcct gctggatgat 180 ggctttggca tggacccctt cccagacgac ttgacagcct cttggcccga ctgggctctg 240 cctcgtctct cctccgcctg gccaggcacc ctaaggtcgg gcatggtgcc ccggggcccc 300 actgccaccg ccaggtttgg ggtgcctgcc gagggcagga cccccccacc cttccctggg 360 gagccctgga aagtgtgtgt gaatgtgcac agcttcaagc cagaggagtt gatggtgaag 420 accaaagatg gatacgtgga ggtgtctggc aaacatgaag agaaacagca agaaggtggc 480 attgtttcta agaacttcac aaagaaaatc cagcttcctg cagaggtgga tcctgtgaca 540 gtatttgcct cactttcccc agagggtctg ctgatcatcg aagctcccca ggtccctcct 600 tactcaacat ttggagagag cagtttcaac aacgagcttc cccaggacag ccaggaagtc 660 acctgtacct gaggatcc 678 <210> 2 <211> 207 <212> PRT <213> Artificial Sequence <220> <223> Tat-HSP22 fusion protein <400> 2 Arg Lys Lys Arg Arg Gln Arg Arg Arg Leu Glu Met Ala Asp Gly Gln 1 5 10 15 Met Pro Phe Ser Cys His Tyr Pro Ser Arg Leu Arg Arg Asp Pro Phe 20 25 30 Arg Asp Ser Pro Leu Ser Ser Arg Leu Leu Asp Asp Gly Phe Gly Met 35 40 45 Asp Pro Phe Pro Asp Asp Leu Thr Ala Ser Trp Pro Asp Trp Ala Leu 50 55 60 Pro Arg Leu Ser Ser Ala Trp Pro Gly Thr Leu Arg Ser Gly Met Val 65 70 75 80 Pro Arg Gly Pro Thr Ala Thr Ala Arg Phe Gly Val Pro Ala Glu Gly 85 90 95 Arg Thr Pro Pro Phe Pro Gly Glu Pro Trp Lys Val Cys Val Asn 100 105 110 Val His Ser Phe Lys Pro Glu Glu Leu Met Val Lys Thr Lys Asp Gly 115 120 125 Tyr Val Glu Val Ser Gly Lys His Glu Glu Lys Gln Gln Glu Gly Gly 130 135 140 Ile Val Ser Lys Asn Phe Thr Lys Lys Ile Gln Leu Pro Ala Glu Val 145 150 155 160 Asp Pro Val Thr Val Phe Ala Ser Leu Ser Pro Glu Gly Leu Leu Ile 165 170 175 Ile Glu Ala Pro Gln Val Pro Pro Tyr Ser Thr Phe Gly Glu Ser Ser 180 185 190 Phe Asn Asn Glu Leu Pro Gln Asp Ser Gln Glu Val Thr Cys Thr 195 200 205
Claims (2)
Wherein the heat shock protein 22 fusion protein is SEQ ID NO: 2. 22. A pharmaceutical composition for preventing or treating cerebral ischemia comprising a heat shock protein 22 fusion protein, wherein the heat shock protein 22 fusion protein is SEQ ID NO:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150111561A KR20170018225A (en) | 2015-08-07 | 2015-08-07 | Pharmaceutical composotion for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150111561A KR20170018225A (en) | 2015-08-07 | 2015-08-07 | Pharmaceutical composotion for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20170018225A true KR20170018225A (en) | 2017-02-16 |
Family
ID=58264847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150111561A KR20170018225A (en) | 2015-08-07 | 2015-08-07 | Pharmaceutical composotion for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20170018225A (en) |
-
2015
- 2015-08-07 KR KR1020150111561A patent/KR20170018225A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102369220A (en) | Target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds and use thereof | |
US7306944B2 (en) | Advanced cell-transducing transport domain-target protein-transport domain fusion protein and uses thereof | |
US20220265837A1 (en) | Complex for intracellular delivery of molecules | |
US8440788B2 (en) | N-terminal VDAC variants and uses thereof | |
KR101869686B1 (en) | Anti-inflammatory pharmaceutical composition containing CIAPIN1 fusion protein | |
KR101764583B1 (en) | Pharmaceutical composition for treating cerebral ischemia containing TXNL1 fusion protein | |
KR20170018225A (en) | Pharmaceutical composotion for treating ischemia containing cell-transducible Heat Shock Protein 22 fusion protein | |
KR101732349B1 (en) | Pharmaceutical composition for treating Parkinson's disease containing cell-transducible PIM2 fusion protein | |
KR101955882B1 (en) | Pharmaceutical composition for treating cerebral ischemia containing RAN fusion protein | |
KR101677449B1 (en) | Pharmaceutical composition for treating ischemia containing cell-transducible NQO1 fusion protein | |
KR20150122280A (en) | Pharmaceutical composition for treating ischemia containing cell-transducible NOL3 fusion protein | |
KR101439203B1 (en) | Pharmaceutical composition containing FK506 binding protein fusion protein and fenobam for treating brain ischemic damage | |
KR101962067B1 (en) | Phmaceutical composition for treating Parkinson's disease containing TXNL1 fusion protein | |
KR101347734B1 (en) | Pharmaceutical composition for parkinson's disease containing rpS3 fusion protein | |
KR20180021470A (en) | Anti-infalmmatory pharmaceutical composition containing Atox1 fusion protein | |
KR20110037536A (en) | Cell transducing glyoxalase fusion protein and pharmaceutical composition containing thereof | |
KR20140030934A (en) | Pharmaceutical composition containing cell-transducing peroxiredoxin 2 fusion protein for brain ischemic damage | |
KR101298014B1 (en) | Cell-transducible PRAS40 fusion protein | |
KR20190036280A (en) | Pharmaceutical composition for treating cerebral ischemia containing Cyclophilin A fusion protein | |
KR20220142557A (en) | Pharmaceutical composition for treating cerebral ischemia containing cell-transducing CRYM fusion protein | |
KR20190111454A (en) | Pharmaceutical composition for treating cerebral ischemia containing GSTA2 fusion protein | |
KR20220139079A (en) | Cell penetrating peptide variants and uses therof | |
KR20160045160A (en) | Pharmaceutical composition for treating ischemia containing glutaredoxin fusion protein | |
KR20220158291A (en) | A pharmaceutical composition containing cell-transducing Inorganic Pyrophosphatase 1 fusion protein for preventing or treating motor neuronal disorder | |
KR20170029671A (en) | Pharmaceutical composition for treating Parkinson's disease containing cell-transducible ATOX1 fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |